Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

Clinical trial NCT06647979 · RECRUITING

Trial details

NCT number: NCT06647979
Sponsor: Daniel Bauer
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Sickle Cell Disease Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)Beta-Thalassemia Transfusion Dependent Beta-Thalassaemia

Start date: 2025-12-01
Primary completion: 2028-12-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.